LuYNiWQuX, et al. Spironolactone for preventing contrast-induced nephropathy after percutaneous coronary intervention in patients with acute myocardial infarction and chronic kidney Disease. Angiology. 2025;76(10):969-980.
WindeckerSKolhPAlfonsoF, et al.2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2014;35:2541.
6.
TsaiTTPatelUDChangTI, et al.Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7:1-9.
7.
AspelinPAubryPFranssonSGStrasserRWillenbrockRBergKJ. Nephrotoxicity in high-risk patients study of I-O and low-osmolar non-ionic contrast media study I. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491.
8.
SolomonR. Contrast media: are there differences in nephrotoxicity among contrast media?BioMed Res Int. 2014;2014:934947.
